Identification of nitroxyl-induced modifications in human platelet proteins using a novel mass spectrometric detection method.
Nitroxyl (HNO) exhibits many important pharmacological effects, including inhibition of platelet aggregation, and the HNO donor Angeli's salt has been proposed as a potential therapeutic agent in the treatment of many diseases including heart failure and alcoholism. Despite this, little is known about the mechanism of action of HNO, and its effects are rarely linked to specific protein targets of HNO or to the actual chemical changes that proteins undergo when in contact with HNO. Here we study the presumed major molecular target of HNO within the body: protein thiols. Cysteine-containing tryptic peptides were reacted with HNO, generating the sulfinamide modification and, to a lesser extent, disulfide linkages with no other long lived intermediates or side products. The sulfinamide modification was subjected to a comprehensive tandem mass spectrometric analysis including MS/MS by CID and electron capture dissociation as well as an MS(3) analysis. These studies revealed a characteristic neutral loss of HS(O)NH2 (65 Da) that is liberated from the modified cysteine upon CID and can be monitored by mass spectrometry. Upon storage, partial conversion of the sulfinamide to sulfinic acid was observed, leading to coinciding neutral losses of 65 and 66 Da (HS(O)OH). Validation of the method was conducted using a targeted study of nitroxylated glyceraldehyde-3-phosphate dehydrogenase extracted from Angeli's salt-treated human platelets. In these ex vivo experiments, the sample preparation process resulted in complete conversion of sulfinamide to sulfinic acid, making this the sole subject of further ex vivo studies. A global proteomics analysis to discover platelet proteins that carry nitroxyl-induced modifications and a mass spectrometric HNO dose-response analysis of the modified proteins were conducted to gain insight into the specificity and selectivity of this modification. These methods identified 10 proteins that are modified dose dependently in response to HNO, whose functions range from metabolism and cytoskeletal rearrangement to signal transduction, providing for the first time a possible mechanistic link between HNO-induced modification and the physiological effects of HNO donors in platelets.
Hoffman
Michael D
MD
The Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada.
Walsh
Geraldine M
GM
Rogalski
Jason C
JC
Kast
Juergen
J
D000595:Amino Acid Sequence; D001792:Blood Platelets / Q000378:metabolism*; D001798:Blood Proteins / Q000032:analysis* / Q000737:chemistry; D003545:Cysteine / Q000378:metabolism; D024581:Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D013058:Mass Spectrometry / Q000379:methods*; D008969:Molecular Sequence Data; D009589:Nitrogen Oxides / Q000378:metabolism*; D010455:Peptides / Q000737:chemistry; D011499:Protein Processing, Post-Translational; D020543:Proteome / Q000032:analysis; D040901:Proteomics; D015203:Reproducibility of Results; D013452:Sulfonium Compounds / Q000378:metabolism; D053719:Tandem Mass Spectrometry
D001798:Blood Proteins; D009589:Nitrogen Oxides; D010455:Peptides; D020543:Proteome; D013452:Sulfonium Compounds; D024581:Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); C039900:nitroxyl; D003545:Cysteine